Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Ian Nakamoto
Bausch & Lomb Inc.BOLDON'T BUYNov 07, 2006
Have been under investigation by the FCC. Also had some product defect.
Ian NakamotoUnknown
$52.50
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
HOLD
Had a misstep on a contact lens solution and the stock dropped to the mid-$40's. He bought at that level, because even if all of their contact lens solution went to zero, they still had other businesses. Recent rumours have driven the stock up to $60.
Pat NaccaratoOwned
biotechnologypharmaceutical
TOP PICK
Has gone through a transition. Was suffering a few years ago when it lost its momentum, R&D lagged. Can see some growth opportunity in their new lens. New president has shaken down the company, cut costs and re-invigorated their R&D. Has exceeded expectations for 13 quarters.
Ian AinsworthOwned
biotechnologypharmaceutical
